Mirum LIVMARLI EXPAND: After Bylvay's $2B Biliary Atresia Wipeout, the Field Is Mirum's to Lose

Mirum Pharmaceuticals sits at $94.12 and a $6.45 billion market cap, down 19% in the past month. The Q2 earnings report on August 5 delivered exactly the kind of mixed message that confuses biotech investors: $176 million in quarterly net product sales, a 37.5% year-over-year jump that beat estimates by $10 million, and full-year guidance raised to $680 to 700 million. Then the stock sank 24% in after-hours trading anyway.

The culprit was not LIVMARLI. The franchise is firing on all cylinders. The culprit was volixibat: Mirum’s second IBAT inhibitor, designed for primary sclerosing cholangitis, just had its NDA timeline pushed from H2 2026 to H1 2027 after the FDA asked for more discussion before submission. When a commercial-stage biotech delays its next pipeline catalyst by six months, the market takes the multiple down. Fair enough.

But buried in that selloff is an asymmetric setup that nobody is talking about. On July 24, Ipsen announced that Bylvay failed its Phase 3 BOLD trial in biliary atresia. The primary endpoint, native liver survival at 104 weeks, did not separate from placebo. Bylvay was the only other IBAT inhibitor in late-stage development for biliary atresia. It failed. Mirum’s EXPAND trial, reading out in Q4 2026, is testing LIVMARLI in the same patient population with a different endpoint, a shorter timeline, and a mechanism that has already produced two FDA approvals. The field is now Mirum’s to lose.

The Biliary Atresia Market: No Approved Drug, One Kasai Procedure, and a Waiting List for Livers

Biliary atresia is a rare pediatric liver disease affecting roughly 340 newborns annually in the United States. The bile ducts are blocked or absent at birth, trapping bile acids in the liver and causing progressive fibrosis. The standard of care is the Kasai hepatoportoenterostomy, a surgical procedure performed in the first few months of life that creates a new drainage pathway. It buys time. It does not fix the disease.

About half of Kasai patients progress to end-stage liver disease and need a transplant before age two. There is no FDA-approved pharmacological therapy for biliary atresia. None. The entire treatment toolkit is surgery and transplant, which is why the EXPAND trial and the BOLD trial before it represented the first real shots at a disease-modifying drug in this space. Orphan drug pricing dynamics apply directly here: a first-in-class approval in a zero-drug market commands premium pricing, and Mirum already has the commercial infrastructure from Alagille syndrome and PFIC.

If LIVMARLI can reduce pruritus in biliary atresia patients the way it does in Alagille syndrome and PFIC, Mirum becomes the first company with an approved drug for a condition that currently has zero. That is not incremental. That is a new market.

EXPAND Trial Design: Why a Pruritus Endpoint at 20 Weeks Beats a Survival Endpoint at 104

The EXPAND study is a Phase 3 randomized, double-blind, placebo-controlled trial evaluating LIVMARLI in patients aged six months and older with cholestatic pruritus from rare cholestatic liver diseases, including biliary atresia. Patients receive maralixibat 285 micrograms per kilogram twice daily or placebo. The primary endpoint is change in pruritus severity from baseline to Week 20. Secondary endpoints include changes in serum bile acids and other markers of cholestatic liver disease. Enrollment was completed in March 2026. Topline data are expected in Q4 2026.

This trial design is meaningfully different from Bylvay’s BOLD trial in three ways that favor Mirum.

First, the endpoint. BOLD tested native liver survival at 104 weeks, a disease-modification endpoint. EXPAND tests pruritus severity at 20 weeks, a symptom endpoint. Symptom endpoints are easier to hit because you are measuring how the patient feels, not whether their liver fails. The FDA has already accepted pruritus improvement as the basis for LIVMARLI’s approvals in Alagille syndrome and PFIC. There is no scientific reason the same endpoint would not translate to biliary atresia patients, who suffer from the same bile acid-driven pruritus.

Second, the timeline. Twenty weeks versus 104 weeks. A shorter trial means less dropout, fewer confounding events, and a cleaner statistical signal. BOLD enrolled 254 patients across 19 countries and still could not generate a positive result on native liver survival because the event rate may simply be too low over two years in a population where half of patients need a transplant anyway.

Third, the mechanism. Maralixibat is an ileal bile acid transporter inhibitor. It blocks bile acid reabsorption in the gut, lowering systemic bile acid levels and reducing the pruritus they cause. This mechanism works regardless of why the bile acids are accumulating. It does not matter whether the diagnosis is Alagille syndrome, PFIC, or biliary atresia. The biology does not care about the disease label. Bylvay uses the same mechanism, which means BOLD’s failure was not a mechanism failure. It was an endpoint failure. The drug probably reduced pruritus in BOLD too, but the trial was not designed to measure it.

What the Data Needs to Show to Move the Stock

Mirum has not disclosed the specific statistical threshold for EXPAND. But based on LIVMARLI’s prior Phase 3 data in Alagille and PFIC, investors should watch for three things.

The pruritus severity change versus placebo needs to show a statistically significant difference with a clinically meaningful effect size. In prior trials, maralixibat reduced pruritus by roughly 1.5 to 2 points on the ItchRO scale versus placebo. A similar magnitude in EXPAND, with a p-value below 0.05, is the hurdle.

Serum bile acid reduction is the secondary endpoint that confirms mechanism. If pruritus improves but bile acids do not drop, the FDA will ask questions. The agency approved LIVMARLI on the strength of both endpoints in Alagille and PFIC.

Safety is the wild card. LIVMARLI carries a liver injury warning. Biliary atresia patients already have liver disease. Any signal of drug-induced liver injury in this population is a label risk, even if the primary endpoint hits.

If EXPAND hits on pruritus with clean safety, Mirum files an sNDA in early 2027, and biliary atresia becomes the third approved indication for the LIVMARLI franchise. The stock re-rates toward $100 to 110. If EXPAND misses, the stock finds support at $80, the level where it traded after the volixibat delay, because LIVMARLI’s $700 million base business still supports a market cap in the mid-$5 billion range.

Bylvay Already Failed. The Competitive Field Is Empty.

The July 24 Bylvay BOLD failure is the single most important data point for evaluating EXPAND’s odds. Ipsen’s odevixibat is the only other approved IBAT inhibitor. It competes with LIVMARLI in PFIC. It just failed Phase 3 in biliary atresia.

The BOLD trial enrolled 254 patients across 19 countries and tested odevixibat 120 mcg/kg/day versus placebo for up to 104 weeks. The primary endpoint was time to liver transplant or death. It missed. Ipsen has not disclosed detailed efficacy data, but the failure was not a safety issue. Odevixibat’s safety profile was consistent with its approved labels.

This means Mirum has a two-year head start in biliary atresia regardless of what EXPAND shows. If the trial hits, the head start becomes a monopoly. No other IBAT inhibitor is in Phase 3 for this indication. Albireo, the original developer of odevixibat, was acquired by Ipsen in 2023 for $1.3 billion. That deal was priced on the PFIC franchise and optionality in biliary atresia. The optionality just expired.

Valuation: $6.45 Billion for a $700 Million Revenue Run-Rate Is Not Cheap

At $94.12 and a $6.45 billion market cap, Mirum trades at roughly 9.2 times forward revenue. That is a premium multiple for rare disease. Compare it to Ionis at roughly 9 times revenue, Ultragenyx at roughly 4 times, and Sarepta at roughly 0.8 times. Mirum’s multiple is in line with Ionis, a company with a deeper pipeline and more near-term catalysts. Both are in our ranked catalyst list for 2026.

The market is paying for the LIVMARLI franchise as it stands, Alagille plus PFIC, and assigning near-zero value to volixibat, brelovitug, or EXPAND. That is the opportunity. If EXPAND succeeds, the market adds biliary atresia to the LIVMARLI revenue model, and the multiple holds. If EXPAND fails, the multiple compresses because the pipeline beyond LIVMARLI has no near-term catalysts until volixibat’s rescheduled NDA in H1 2027.

The right comp is actually Mirum versus itself six months ago. Before the volixibat delay, Mirum traded above $110. The delay accounted for roughly 14% of the market cap. An EXPAND success restores that confidence in the pipeline. An EXPAND failure reinforces the single-franchise discount.

Risks: The Volixibat Overhang and the Single-Franchise Problem

The volixibat delay is the structural headwind that caps Mirum’s multiple until resolved. VISTAS Phase 2b data showed rapid and sustained pruritus reductions in PSC, and the FDA granted Breakthrough Therapy designation. But the agency is asking for more discussion before NDA submission. In FDA-speak, that means the Phase 2b data alone may not be enough for accelerated approval, and the agency wants Phase 3 data or a longer safety database. That timeline is now H1 2027, and it could slip further.

Bre lovitug for hepatitis delta virus reads out Phase 3 data in H2 2026, but HDV is a smaller market than PSC and the data are unproven. MRM-3379 for Fragile X syndrome is preclinical.

The risk for EXPAND specifically is that the pruritus endpoint does not translate from Alagille/PFIC to biliary atresia. The patient population is younger. The disease biology is different. The bile acid accumulation may not cause pruritus in the same way. If EXPAND fails on pruritus, Mirum cannot fall back on a survival endpoint the way Ipsen tried with BOLD. The rare disease trial design challenges are real: small patient populations, heterogeneous disease progression, and endpoints that work in one indication but not in another.

Verdict

Bylvay’s failure in biliary atresia is a gift to Mirum shareholders. It removed the only direct competitor and validated the strategic logic of running a pruritus endpoint instead of a survival endpoint. EXPAND is testing exactly what LIVMARLI is already approved to treat, cholestatic pruritus, in a new population. The mechanism is the same. The endpoint is the same. The only question is whether the population responds the same way.

At $94.12, the stock has already repriced the volixibat delay. An EXPAND success in Q4 adds biliary atresia to the franchise and supports a re-rate back above $110. An EXPAND failure drops the stock to the $80 support level, where the base business is worth roughly 7 times forward revenue. That is a $14 upside versus $14 downside on a binary catalyst. A coin flip at even money.

I would not size a full position here. The volixibat overhang is real, and EXPAND is still a Phase 3 binary. But a 1 to 2 percent portfolio allocation bought into the August weakness, ahead of a Q4 catalyst with an empty competitive field, is the right setup. If you wait for the stock to recover to $100 before EXPAND, you have already missed the asymmetry.

Correction Note: The original brief stated that EXPAND would test label expansion into Alagille syndrome. LIVMARLI has been FDA-approved for cholestatic pruritus in Alagille syndrome since September 2021. The actual EXPAND trial tests label expansion into biliary atresia and other rare cholestatic liver diseases for which LIVMARLI is not currently approved. This correction was confirmed via Mirum’s March 16, 2026 press release and ClinicalTrials.gov.